Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2009; 53:667-677, doi:10.1016/j.jacc.2008.10.047
© 2009 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Related Cardiosource Journal Scan
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Santilli, F.
Right arrow Articles by Patrono, C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Santilli, F.
Right arrow Articles by Patrono, C.
Related Collections
Right arrowRelated Articles

CLINICAL RESEARCH: ANTIPLATELET THERAPY

Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays

Implications for Aspirin "Resistance"

Francesca Santilli, MD*, Bianca Rocca, MD, PhD{dagger}, Raimondo De Cristofaro, MD{ddagger}, Stefano Lattanzio, BSc*, Laura Pietrangelo, BSc*, Aida Habib, PhD§, Caterina Pettinella, PhD*, Antonio Recchiuti, PhD*, Elisabetta Ferrante, BSc*, Giovanni Ciabattoni, MD*, Giovanni Davì, MD* and Carlo Patrono, MD{dagger},*

* Center of Excellence on Aging, "G. d'Annunzio" University Foundation, Chieti, Italy
{dagger} Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
{ddagger} Department of Internal Medicine, Catholic University School of Medicine, Rome, Italy
§ American University of Beirut, Beirut, Lebanon

Manuscript received July 25, 2008; revised manuscript received October 8, 2008, accepted October 14, 2008.

* Reprint requests and correspondence: Prof. Carlo Patrono, Department of Pharmacology, Catholic University School of Medicine, Largo F. Vito 1 00168 Rome, Italy (Email: carlo.patrono{at}rm.unicatt.it).

Objective: This study was conducted to assess the thromboxane (TX) dependence of biochemical and functional indexes used to monitor the effect of low-dose aspirin.

Background: Functional assays of the antiplatelet effects of low-dose aspirin variably reflect the TX-dependent component of platelet aggregation. Previous studies of aspirin resistance were typically based on a single determination of platelet aggregation.

Methods: We assessed the TXB2 dependence of biochemical and functional indexes, as well as their intersubject and intrasubject variability during administration of the drug and after its withdrawal in 48 healthy volunteers randomized to receive aspirin 100 mg daily for 1 to 8 weeks.

Results: Serum TXB2 was uniformly suppressed by 99% of baseline. Urinary 11-dehydro-TXB2, arachidonic acid-induced aggregation, and VerifyNow Aspirin (Accumetrics Inc., San Diego, California) showed stable, incomplete inhibition (65%, 80%, and 35%, respectively). Adenosine diphosphate- and collagen-induced aggregation was highly variable and poorly affected by aspirin, with an apparent time-dependent reversal. Inhibition of platelet cyclooxygenase activity was nonlinearly related to inhibition of platelet aggregation. Platelet function largely recovered by day 3 post-aspirin, independently of treatment duration. With any functional assay, occasionally "resistant" subjects were found to be "responders" on previous or subsequent determinations.

Conclusions: Platelet cyclooxygenase activity, as reflected by serum TXB2 levels, is uniformly and persistently suppressed by low-dose aspirin in healthy subjects. However, the effect of aspirin is variably detected by functional assays, potentially leading to misclassification of "responder" as "resistant" phenotypes owing to poor reproducibility of functional measurements. The nonlinearity of the relationship between inhibition of TX production and inhibition of platelet function has important clinical implications.

Key Words: aspirin • platelets • prostaglandins • antiplatelet drugs • pharmacology

Abbreviations and Acronyms
  AA = arachidonic acid
  ADP = adenosine diphosphate
  COX = cyclooxygenase
  CV = coefficient of variation
  NSAID = nonsteroidal anti-inflammatory drug
  Tmax = maximal aggregation
  TX = thromboxane


Related Articles

Aspirin Resistance: Transient Laboratory Finding or Important Clinical Entity?
Eli I. Lev
J. Am. Coll. Cardiol. 2009 53: 678-680. [Full Text] [PDF]

Inside This Issue
J. Am. Coll. Cardiol. 2009 53: A21-A24. [Full Text] [PDF]



This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
E. I. Lev
Aspirin resistance transient laboratory finding or important clinical entity?
J. Am. Coll. Cardiol., February 24, 2009; 53(8): 678 - 680.
[Full Text] [PDF]


Home page
Mol. Interv.Home page
C. Patrono and C. Baigent
Low-Dose Aspirin, Coxibs, and other NSAIDS: A Clinical Mosaic Emerges
Mol. Interv., February 1, 2009; 9(1): 31 - 39.
[Abstract] [Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement